Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis

Condition(s) studied

Study summary

The main objective was to evaluate the clinical efficacy of PD-1 inhibitor (PD-1 monoclonal antibody) in the treatment of skin and subcutaneous mucocytosis infection, including the comparison of immune cell groups before and after treatment, the changes in the proportion of CD4+T cells and CD8+T cells, and the changes in the inflammatory cytokines of the serum after co-culture of human peripheral blood mononuclear cells (PBMC) with fungi before and after treatment. The improvement of lesions and the relief of symptoms. The secondary objective is to evaluate the safety of PD-1 inhibitors during treatment, including monitoring and recording all adverse events and immune-related adverse reactions.

Eligibility

Primary outcome measure(s)

• Changes in CD4 T cells and CD8 T cells — through study completion, an average of 1 month
  Changes in CD4 T cells and CD8 T cells：through study completion, an average of 1 month

Trial sites (1)

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China